Glipizide
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Glipizide: From Type 2 Diabetes to Opsismodysplasia
One-Sentence Summary
Glipizide is a second-generation sulfonylurea used to manage type 2 diabetes mellitus by stimulating pancreatic β-cell insulin secretion. The TxGNN model predicts a possible association with Opsismodysplasia, a rare skeletal dysplasia, but this prediction is currently supported by 0 clinical trials and 0 publications, and the evidence pack’s own mechanistic review flags it as a likely embedding-space artefact rather than a genuine signal.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Type 2 diabetes mellitus (inferred from mechanism-of-action references within the evidence pack; not provided as a structured field) |
| Predicted New Indication | Opsismodysplasia |
| TxGNN Prediction Score | 98.77% |
| Evidence Level | L5 (model prediction only, no supporting studies) |
| Australia Market Status | Not marketed |
| Number of ARTG Entries | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data for glipizide was not returned as a structured field in this evidence pack (flagged as a High-severity data gap). However, the evidence pack’s own rationale text for related candidates consistently describes glipizide’s known pharmacology as a sulfonylurea that acts on pancreatic β-cell KATP channels to stimulate insulin secretion — the standard mechanism for glucose control in type 2 diabetes.
Opsismodysplasia is a rare skeletal dysplasia caused by mutations in the INO80D gene, affecting chromatin remodelling during bone development. Based on the evidence pack’s mechanistic assessment, there is no identifiable biological pathway connecting glipizide’s insulin-secretagogue action to INO80D-mediated skeletal development — the two conditions do not share any known receptor, enzyme, or signalling pathway.
The evidence pack’s own reviewer explicitly assesses this candidate as likely high-score noise in the TxGNN embedding space rather than a genuine repurposing signal. This assessment is consistent with the complete absence of clinical or literature evidence below, and is reinforced by the fact that several other top-ranked predictions for this drug (e.g. stiff person syndrome variants, lipodystrophy subtypes) were independently flagged with the same “no mechanistic pathway” conclusion — suggesting this cluster of high TxGNN scores may reflect a systematic embedding artefact rather than a disease-specific signal.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Australia Market Information
No ARTG entries were found — glipizide is not currently marketed in Australia under this evidence pack (0 licences on record).
Safety Considerations
Please refer to the TGA-approved Product Information (PI) for safety information. No key warnings, contraindications, or drug interaction data were available in this evidence pack (TFDA/PI warning data is flagged as a Blocking data gap).
Conclusion and Next Steps
Decision: Hold
Rationale: There is no clinical, literature, or plausible mechanistic evidence linking glipizide to opsismodysplasia — the drug’s evidence pack itself assesses this top-ranked prediction as likely embedding-space noise rather than a genuine repurposing candidate. Combined with the drug’s current non-marketed status in Australia, this candidate does not warrant progression at this time.
To proceed, the following is needed:
- TFDA/TGA-equivalent Product Information (warnings, contraindications) — currently a Blocking data gap
- Confirmed mechanism-of-action documentation from DrugBank — currently a High-severity data gap
- Independent biological rationale (e.g. genetic, cellular, or animal model data) connecting sulfonylurea pharmacology to INO80D-related skeletal development, before any further evidence collection is justified
- Given the pattern of similarly unsupported high-scoring predictions for this drug, consider a broader review of whether this TxGNN embedding cluster is reliable before investing further review effort
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.